PRAKASH MASAND to Aged
This is a "connection" page, showing publications PRAKASH MASAND has written about Aged.
Connection Strength
0.225
-
Clinical effectiveness of atypical antipsychotics in elderly patients with psychosis. Eur Neuropsychopharmacol. 2004 Nov; 14 Suppl 4:S461-9.
Score: 0.061
-
Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging. 2003; 20(15):1099-110.
Score: 0.054
-
Quetiapine augmentation for depression: dosing pattern in routine practice. Int Clin Psychopharmacol. 2015 Jan; 30(1):54-8.
Score: 0.031
-
A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009 Jan-Feb; 50(1):78-86.
Score: 0.020
-
Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. Eur Arch Psychiatry Clin Neurosci. 2020 Oct; 270(7):901-910.
Score: 0.011
-
Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. J Affect Disord. 2019 Apr 15; 249:410-417.
Score: 0.010
-
A prospective multicenter study of competency evaluations by psychiatric consultation services. Psychosomatics. 1998 Jan-Feb; 39(1):55-60.
Score: 0.010
-
Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. J Mol Neurosci. 2018 Jan; 64(1):62-74.
Score: 0.009
-
Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Adv Ther. 2017 06; 34(6):1482-1497.
Score: 0.009
-
Paroxetine: safety and tolerability issues. Expert Opin Drug Saf. 2008 Nov; 7(6):783-94.
Score: 0.005
-
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006 Dec; 26(6):653-6.
Score: 0.004